Skip to main content

Welkom bij Scalda & Bohn Stafleu van Loghum

Scalda heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen.Je kunt de producten hieronder links aanschaffen en rechts inloggen.

Registreer

Schaf de BSL Academy aan: 

BSL Academy mbo AG

Eenmaal aangeschaft kun je thuis, of waar ook ter wereld toegang krijgen tot Mijn BSL.

Heb je een vraag, neem dan contact op met Jan van der Velden.

Login

Als u al geregistreerd bent, hoeft u alleen maar in te loggen om onbeperkt toegang te krijgen tot Mijn BSL.

Top
Gepubliceerd in:

01-12-2003 | Kleine kwalen

Fenomeen van Raynaud en wintertenen

Auteurs: V van der Meer, LC de Jong-Potjer, JAH Eekhof, A Knuistingh Neven

Gepubliceerd in: Huisarts en wetenschap | Uitgave 13/2003

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Verkleurde pijnlijke vingers of tenen bij lage omgevingstemperatuur, dat zijn de kenmerkende verschijnselen van het fenomeen van Raynaud (FR) en wintertenen. Prevalentiecijfers van FR variëren van 5% tot 21% afhankelijk van geografische variatie, sekse en definitie.
Literatuur
go back to reference Hildegard MR, Carpentier PH, Weinrich MC, Keil JE, Franco A, Drouet P, et al. Geographic variation in the prevalence of Raynaud's phenomenon: Charleston, SC, USA vs Tarentaise, Savoie, France. J Rheumatol 1993;20:70-6. Hildegard MR, Carpentier PH, Weinrich MC, Keil JE, Franco A, Drouet P, et al. Geographic variation in the prevalence of Raynaud's phenomenon: Charleston, SC, USA vs Tarentaise, Savoie, France. J Rheumatol 1993;20:70-6.
go back to reference Silman A, Holligan S, Brennan P, Maddison P. Prevalence of symptoms of Raynaud's phenomenon in general practise. BMJ 1990;301:590-2.CrossRefPubMed Silman A, Holligan S, Brennan P, Maddison P. Prevalence of symptoms of Raynaud's phenomenon in general practise. BMJ 1990;301:590-2.CrossRefPubMed
go back to reference Freedman RR, Dayes MD. Familial aggregation of primary Raynaud's disease. Arthritis Rheum 1996;39:1189-1201.CrossRefPubMed Freedman RR, Dayes MD. Familial aggregation of primary Raynaud's disease. Arthritis Rheum 1996;39:1189-1201.CrossRefPubMed
go back to reference Okkes IM, Oskam SK, Lamberts H. Van klacht naar diagnose. Episodegegevens uit de huisartspraktijk. Boek met CD-ROM. Bussum: Coutinho, 1998. Okkes IM, Oskam SK, Lamberts H. Van klacht naar diagnose. Episodegegevens uit de huisartspraktijk. Boek met CD-ROM. Bussum: Coutinho, 1998.
go back to reference Ong RSG, De Waal MWM. RHUH-LEO basisrapport X: databestand 2000/2001. Leiden: LUMC Afdeling Huisartsgeneeskunde en Verpleeghuisgeneeskunde, 2002. Ong RSG, De Waal MWM. RHUH-LEO basisrapport X: databestand 2000/2001. Leiden: LUMC Afdeling Huisartsgeneeskunde en Verpleeghuisgeneeskunde, 2002.
go back to reference Van Leusden HAIM, redactie. Diagnostisch Kompas 1999/2000. Amstelveen: Commissie Aanvullende Diagnostiek van het College voor Zorgverzekeringen, 1999. Van Leusden HAIM, redactie. Diagnostisch Kompas 1999/2000. Amstelveen: Commissie Aanvullende Diagnostiek van het College voor Zorgverzekeringen, 1999.
go back to reference LeRoy EC, Medsger TA Jr. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol 1992;10:485-8.PubMed LeRoy EC, Medsger TA Jr. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol 1992;10:485-8.PubMed
go back to reference Spencer-Green G. Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary disease. Arch Intern Med 1998;158:595-600.CrossRefPubMed Spencer-Green G. Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary disease. Arch Intern Med 1998;158:595-600.CrossRefPubMed
go back to reference Freedman RR, Baer RP, Mayes MD. Blockade of vasospastic attacks by alpha 2-adrenergic but not alpha 1-adrenergic antagonists in idiopathic Raynaud's disease. Circulation 1995;92:1448-9.PubMed Freedman RR, Baer RP, Mayes MD. Blockade of vasospastic attacks by alpha 2-adrenergic but not alpha 1-adrenergic antagonists in idiopathic Raynaud's disease. Circulation 1995;92:1448-9.PubMed
go back to reference Susol E, MacGregor AJ, Barrett JH, Wilson H, Black C, Welsh K, Silman A, et al. A two-stage, genome-wide screen for susceptibility loci in primary Raynaud's phenomenon. Arthritis Rheum 2000;43:1641-6.CrossRefPubMed Susol E, MacGregor AJ, Barrett JH, Wilson H, Black C, Welsh K, Silman A, et al. A two-stage, genome-wide screen for susceptibility loci in primary Raynaud's phenomenon. Arthritis Rheum 2000;43:1641-6.CrossRefPubMed
go back to reference Carruthers R. Chilblains (perniones). Aust Fam Physician 1988;17: 968-9.PubMed Carruthers R. Chilblains (perniones). Aust Fam Physician 1988;17: 968-9.PubMed
go back to reference Smilde TJ, Wollersheim H. Therapeutische (on)mogelijkheden bij het fenomeen van Raynaud. Ned Tijdschr Geneeskd 1996;140:352-7.PubMed Smilde TJ, Wollersheim H. Therapeutische (on)mogelijkheden bij het fenomeen van Raynaud. Ned Tijdschr Geneeskd 1996;140:352-7.PubMed
go back to reference Raynaud's treatment study investigators. Comparison of sustainedrelease nifedipine and temperature biofeedback for treatment of primary Raynaud's phenomenon: results from a randomized clinical trial with 1-year follow-up. Arch Intern Med 2000;160:1101-8. Raynaud's treatment study investigators. Comparison of sustainedrelease nifedipine and temperature biofeedback for treatment of primary Raynaud's phenomenon: results from a randomized clinical trial with 1-year follow-up. Arch Intern Med 2000;160:1101-8.
go back to reference Challenor VF, Waller DG, Hayward RA, Griffin MJ, Roath OS. Vibrotactile sensation and response to nifedipine dose titration in primary Raynaud's phenomenon. Angiology 1989;40:122-8.CrossRefPubMed Challenor VF, Waller DG, Hayward RA, Griffin MJ, Roath OS. Vibrotactile sensation and response to nifedipine dose titration in primary Raynaud's phenomenon. Angiology 1989;40:122-8.CrossRefPubMed
go back to reference Sarkozi J, Bookman AA, Mahon W, Ramsay C, Detsky AS, Keystone EC. Nifedine in the treatment of idiopathic Raynaud's syndrome. J Rheumatol 1986;13:331-6.PubMed Sarkozi J, Bookman AA, Mahon W, Ramsay C, Detsky AS, Keystone EC. Nifedine in the treatment of idiopathic Raynaud's syndrome. J Rheumatol 1986;13:331-6.PubMed
go back to reference Gjorup T, Kelbaek H, Hartling OJ, Nielsen SL. Controlled doubleblind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenon. Am Heart J 1986;111:742-5.CrossRefPubMed Gjorup T, Kelbaek H, Hartling OJ, Nielsen SL. Controlled doubleblind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenon. Am Heart J 1986;111:742-5.CrossRefPubMed
go back to reference Corbin DO, Wood DA, Macintyre CC, Housley E. A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon. Eur Heart J 1986;7:165-70.PubMed Corbin DO, Wood DA, Macintyre CC, Housley E. A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon. Eur Heart J 1986;7:165-70.PubMed
go back to reference Ferri C, Cecchetti R, Cini G, Gambini I, La Civita L, Bernini L, et al. Slow-releasing nicardipine in the treatment of Raynaud's phenomenon without underlying diseases. Clin Rheumatol 1992;11:76-80.CrossRefPubMed Ferri C, Cecchetti R, Cini G, Gambini I, La Civita L, Bernini L, et al. Slow-releasing nicardipine in the treatment of Raynaud's phenomenon without underlying diseases. Clin Rheumatol 1992;11:76-80.CrossRefPubMed
go back to reference Controlled multicenter double-blind trial of nicardipine in the treatment of primary Raynaud phenomenon. French Cooperative Multicenter Group of Raynaud Phenomenon, Paris, France. Am Heart J 1991;122:352-5. Controlled multicenter double-blind trial of nicardipine in the treatment of primary Raynaud phenomenon. French Cooperative Multicenter Group of Raynaud Phenomenon, Paris, France. Am Heart J 1991;122:352-5.
go back to reference Kallenberg CG, Wouda AA, Mems L, Wesseling H. Once daily felodipine in patients with primary Raynaud's phenomenon. Eur J Clin Pharmacol 1991;40:313-5.CrossRefPubMed Kallenberg CG, Wouda AA, Mems L, Wesseling H. Once daily felodipine in patients with primary Raynaud's phenomenon. Eur J Clin Pharmacol 1991;40:313-5.CrossRefPubMed
go back to reference Leppert J, Jonasson T, Nilsson H, Ringqvist I. The effect of isradipine, a new calcium-channel antagonist, in patients with primary Raynaud's phenomenon: a single-blind dose-response study. Cardiovasc Drugs Ther 1989;3:397-401.CrossRefPubMed Leppert J, Jonasson T, Nilsson H, Ringqvist I. The effect of isradipine, a new calcium-channel antagonist, in patients with primary Raynaud's phenomenon: a single-blind dose-response study. Cardiovasc Drugs Ther 1989;3:397-401.CrossRefPubMed
go back to reference Gjorup T, Hartling OJ, Kelbaek H, Nielsen SL. Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon. Eur J Clin Pharmacol 1986;31:387-9.CrossRefPubMed Gjorup T, Hartling OJ, Kelbaek H, Nielsen SL. Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon. Eur J Clin Pharmacol 1986;31:387-9.CrossRefPubMed
go back to reference Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001;44:1841-7.CrossRefPubMed Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001;44:1841-7.CrossRefPubMed
go back to reference Nielsen SL, Vitting K, Rasmussen K. Prazosin treatment of primary Raynaud's phenomenon. Eur J Clin Pharmacol 1983;24:421-3.CrossRefPubMed Nielsen SL, Vitting K, Rasmussen K. Prazosin treatment of primary Raynaud's phenomenon. Eur J Clin Pharmacol 1983;24:421-3.CrossRefPubMed
go back to reference Wollersheim H, Thien T, Fennis J, Van Elteren P, Van ’t Laar A. Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon. Clin Pharmacol Ther 1986;40:219-25.PubMed Wollersheim H, Thien T, Fennis J, Van Elteren P, Van ’t Laar A. Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon. Clin Pharmacol Ther 1986;40:219-25.PubMed
go back to reference Surwit RS, Allen LM 3rd, Gilgor RS, Duvic M. The combined effect of prazosin and autogenic training on cold reactivity in Raynaud's phenomenon. Biofeedback Self Regul 1982;7:537-44.CrossRefPubMed Surwit RS, Allen LM 3rd, Gilgor RS, Duvic M. The combined effect of prazosin and autogenic training on cold reactivity in Raynaud's phenomenon. Biofeedback Self Regul 1982;7:537-44.CrossRefPubMed
go back to reference Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, et al. Prazosin for Raynaud's phenomenon in progressive systemic sclerosis (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, et al. Prazosin for Raynaud's phenomenon in progressive systemic sclerosis (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software.
go back to reference Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, et al. Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, et al. Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software.
go back to reference Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallelgroup, controlled trial. Arthritis Rheum 1999;42:2646-55.CrossRefPubMed Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallelgroup, controlled trial. Arthritis Rheum 1999;42:2646-55.CrossRefPubMed
go back to reference Pancera P, Sansone S, Secchi S, Covi G, Lechi A. The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud's phenomenon. J Intern Med 1997;242:373-6.CrossRefPubMed Pancera P, Sansone S, Secchi S, Covi G, Lechi A. The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud's phenomenon. J Intern Med 1997;242:373-6.CrossRefPubMed
go back to reference Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, Black CM. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology 2001;40:1038- 43.CrossRefPubMed Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, Black CM. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology 2001;40:1038- 43.CrossRefPubMed
go back to reference Denton CP, Howell K, Stratton RJ, Black CM. Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study. Clin Exp Rheumatol 2000;18:499-502.PubMed Denton CP, Howell K, Stratton RJ, Black CM. Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study. Clin Exp Rheumatol 2000;18:499-502.PubMed
go back to reference Leh LS, Manning J, More T, Tully MP, O'Reilly D, Jayson MI. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. Br J Rheumatol. 1995;34:636-41.CrossRef Leh LS, Manning J, More T, Tully MP, O'Reilly D, Jayson MI. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. Br J Rheumatol. 1995;34:636-41.CrossRef
go back to reference Rustin MH, Newton JA, Smith NP, Dowd PM. The treatment of chilblains with nifedipine: the results of a pilot study, a double-blind placebo-controlled randomized study and a long-term open trial. Br J Dermatol 1989;120:267-75.CrossRefPubMed Rustin MH, Newton JA, Smith NP, Dowd PM. The treatment of chilblains with nifedipine: the results of a pilot study, a double-blind placebo-controlled randomized study and a long-term open trial. Br J Dermatol 1989;120:267-75.CrossRefPubMed
Metagegevens
Titel
Fenomeen van Raynaud en wintertenen
Auteurs
V van der Meer
LC de Jong-Potjer
JAH Eekhof
A Knuistingh Neven
Publicatiedatum
01-12-2003
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Huisarts en wetenschap / Uitgave 13/2003
Print ISSN: 0018-7070
Elektronisch ISSN: 1876-5912
DOI
https://doi.org/10.1007/BF03083203